Press release -
Chr. Hansen's newest silage inoculant approved
Biomax® GP, Chr. Hansen's newest product, has been approved by internationally acknowledged German Agricultural Society (DLG). Biomax® GP improves fermentation and the feeding value of silages for dairy cows.
'Biomax® GP, combines our two most powerful acidifying strains to enhance preservation of grass and lucerne silages. In addition to improving fermentation, Biomax® GP also reduces the risk of loss, increases silage digestibility and maximizes animal performance, which in turn will generate substan-tial and consistent returns on investment.' - explains Dr. David Seale, Chr. Hansen's expert on silage production.
Biomax GP improves feed intake of dairy cows
The DLG approval confirms that Biomax® GP improves silage fermentation of silages with different dry matters which is important for farmers since weather conditions are often unpredictable and silage dry matter may change rapidly. Biomax GP improves feed intake of dairy cows for which silage is the most important and less costly feedstuff. Higher feed intake combined with better digestibility result in more nutrients available for the milk production of the cow.
'We develop our products with the aim to increase the profitability of milk production. Our products are based on selected strains of lactic acid producing bacteria that help to preserve the nutrients in animal feed. We use state-of-the-art research technology and independent research institutes to de-velop and test our products. We see the DLG approval as an acknowledgment that by using Biomax® GP farmers can improve the nutritive value of silage', explains Peter Kürti, Sales & Marketing Director, Chr. Hansen.
Product quality and consistency
Chr. Hansen was the first company to achieve FAMI-QS for silage inoculants; an overall certification, which combines ISO 9001 standard, GMP (Good Manufacturing Practice) and HACCP requirements (Hazard Analysis and Critical Control Points) in one certification. In combination with our unique stabilization technology and 130 years of experience in producing microbial cultures, this ensures product quality and consistency.
Topics
Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2013/14 financial year was EUR 756 million. The company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition and Natural Colors. It has more than 2,500 dedicated employees in over 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on NASDAQ OMX Copenhagen.